文献速递肝病

口服甜菜碱治疗代谢功能障碍相关脂肪性肝病伴转氨酶升高的试点试验

Pilot trials of oral betaine in participants with metabolic dysfunction-associated steatotic liver disease and elevated alanine aminotransferase.
PubMed 文献 · Hepatology · 2025-08-04

三项试点试验评估低剂量甜菜碱在临床诊断的非肝硬化MASLD且ALT≥50 U/L患者中的安全性和有效性。每日8、4、2克甜菜碱12-24周显著降低ALT、AST、细胞角蛋白18、pro-C3和MASEF评分,1克剂量无效。约35%报告轻度短暂胃肠道症状。

要点

  • 甜菜碱8、4、2克/天可显著降低MASLD患者ALT及其他肝损伤血清标志物。
  • 1克/天剂量未观察到显著疗效。
  • 约35%参与者出现轻度短暂胃肠道症状。

核心结论

  • 甜菜碱8、4、2克/天持续12-24周可显著降低临床定义MASLD且ALT升高患者的ALT及其他肝损伤血清标志物。

研究设计与样本

  • 三项试点试验纳入临床诊断的非肝硬化MASLD且ALT≥50 U/L的参与者。
  • 第一项试验44人随机接受每日4或8克治疗12周;第二项试验10人接受每日1克治疗24周;第三项试验16人接受每日2克治疗24周。
  • 主要结局为ALT异常成分(男性ALT>30或女性>25)的百分比下降,基线及治疗结束数据采用配对t检验比较。

主要发现

  • 接受8、4、2克甜菜碱的参与者ALT、AST、细胞角蛋白18、pro-C3和MASEF评分显著下降,1克组无显著变化。
  • 4克和2克组高密度脂蛋白升高,低密度脂蛋白无变化。
  • 约35%报告轻度、短暂的胃肠道症状。
  • 基线时超过75%的参与者经MASEF评分检测符合NASH。

关键数值与推荐

  • 主要结局为ALT异常成分的百分比下降,异常定义为男性ALT>30 U/L或女性>25 U/L。
  • 其他结局包括绝对ALT和AST改善及其他肝损伤血清学检测(MASEF评分、细胞角蛋白18、pro-C3)。

临床怎么用

  • 对于临床诊断MASLD且ALT≥50 U/L的非肝硬化患者,可考虑使用甜菜碱8、4或2克/天改善肝损伤血清标志物。
  • 1克/天剂量可能无效,不推荐使用。
  • 需注意约35%患者可能出现轻度短暂胃肠道症状。

局限性

  • 试点试验样本量小(第一项44人,第二项10人,第三项16人)。
  • 缺乏安慰剂对照,采用配对t检验比较基线及治疗结束数据。
  • 临床诊断MASLD而非组织学确诊,基线时超过75%经MASEF评分符合NASH。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Betaine, 20 g/day for 12 months, reduced liver injury in several trials in non-alcoholic steatohepatitis (NASH). Our aim was to determine the safety and efficacy of lower doses of betaine in clinically diagnosed metabolic dysfunction-associated steatotic liver disease (MASLD) and an elevated ALT. APPROACH AND RESULTS: We performed 3 pilot trials in participants with clinically diagnosed non-cirrhotic MASLD and ALT ≥50 U/L. In the first trial, 44 participants were randomized to 4 or 8 g daily for 12 weeks. In the second trial, 10 participants received 1 g/day for 24 weeks, while 16 participants received 2 g/day for 24 weeks in the third trial. The primary outcome was the percent decline in the abnormal component of ALT (ie, ALT >30 for males or >25 for females). Other outcomes included improvement in absolute ALT and AST, and other serologic tests of liver injury, including metabolomics-advanced steatohepatitis fibrosis (MASEF) score, cytokeratin 18, and pro-C3. Baseline and end-of-treatment data were compared with a paired t test. At baseline, more than 75% of participants had NASH when tested by the MASEF score. ALT, AST, cytokeratin 18, pro-C3, and MASEF score decreased significantly among participants receiving 8, 4, and 2 g, but not 1 g. High-density lipoprotein increased in the 4 and 2 g cohorts; low-density lipoprotein did not change. Approximately 35% reported mild, transient gastrointestinal symptoms. CONCLUSIONS: Betaine 8, 4, and 2 g/day for 12-24 weeks significantly reduced ALT and other serologic markers of liver injury among participants with clinically defined MASLD and an elevated ALT.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Lim AS, Cruz SN, Uddin AA, et al. Pilot trials of oral betaine in participants with metabolic dysfunction-associated steatotic liver disease and elevated alanine aminotransferase. Hepatology. 2025. PMID: 40758380. doi:10.1097/HEP.0000000000001477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。